Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (262)
  2. Journal Article (245)
  3. Review (26)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (573)
  2. Gastrointestinal Oncology Service (573)
  3. Solid Tumor Oncology Division (573)
  4. Center for Pancreatic Cancer Research (215)
  5. Epidemiology and Biostatistics (122)
  6. Surgery (103)

More Groups

People
  1. Eileen O'Reilly (156)
  2. James Harding (130)
  3. William Jarnagin (66)
  4. Marinela Capanu (65)
  5. Leonard Saltz (55)
  6. Imane El Dika (54)

More People

Years
  1. 2025 (18)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (166)
  2. Annals of Oncology (53)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (182)
  2. Oxford University Press (65)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (573)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1B trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC)
    Meeting Abstract

    Lowery, M. A.; Capanu, M.; Glassman, D. C.; Covington, C. M.; Gluskin, J.; Brenner, R.; Li, C. F.; Bomalaski, J. S.; Johnston, A.; Barba, A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype
    Meeting Abstract

    Jordan, E.; Lowery, M. A.; Ptashkin, R.; Zehir, A.; Berger, M. F.; Maynard, H.; Glassman, D. C.; Covington, C. M.; Schultz, N.; Abou-Alfa, G. K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Heins, Z. J.; Connell, L. C.; Soumerai, T.; Kemeny, N. E.; Jarnagin, W. R.; O'Reilly, E. M.; DeMatteo, R. P.; D'Angelica, M. I.; Lowery, M. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis
    Meeting Abstract

    Goff, L. W.; Lowery, M. A.; Jordan, E.; Wang, R.; Bocobo, A. G.; Chou, J. F.; O'Reilly, E. M.; Harding, J. J.; Kemeny, N. E.; Capanu, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy
    Meeting Abstract

    Abou-Alfa, G. K.; Galle, P. R.; Chao, Y.; Brown, K. T.; Heo, J.; Borad, M. J.; Luca, A.; Pelusio, A.; Agathon, D.; Lusky, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Abou-Alfa, G. K.; Qin, S.; Ryoo, B. Y.; Lu, S. N.; Yen, C. J.; Feng, Y. H.; Lim, H. Y.; Izzo, F.; Colombo, M.; Sarker, D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
    Meeting Abstract

    Abou-Alfa, G. K.; Niedzwieski, D.; Knox, J. J.; Kaubisch, A.; Posey, J.; Tan, B. R.; Kavan, P.; Goel, R.; Lammers, P. E.; Bekaii-Saab, T. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)
    Meeting Abstract

    Abou-Alfa, G. K.; Sangro, B.; Morse, M.; Zhu, A. X.; Kim, R. D.; Cheng, A. L.; Kudo, M.; Kang, Y. K.; Chan, S. L.; Antal, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Detection of IDH1 mutations in circulating free DNA in patients with cholangiocarcinoma
    Meeting Abstract

    Lowery, M. A.; You, D.; Samoila, A.; Peerschke, E.; Viale, A.; Patel, R.; Selcuklu, D.; Rusek, M.; Cercek, A.; Kemeny, N.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Yoon, J. H.; Modiano, M.; Ryoo, B. Y.; Yau, T.; Freilich, B.; Knox, J.; Ly, M.; Ahmed, H.; Gahir, S.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save